EPA Test · Blood

If you eat fish regularly, take an omega-3 supplement, or do neither, your EPA (eicosapentaenoic acid) level tells you whether your body actually has enough of this protective fat where it counts. EPA is one of the two main marine omega-3 fatty acids, and among the two, it has the most consistent track record for reducing heart attacks and cardiovascular death in large clinical trials.

What makes EPA especially useful as a biomarker is that your blood level reflects weeks of dietary intake, not just last night's dinner. A single reading gives you a reliable snapshot of your omega-3 status, and unlike cholesterol, which your body manufactures on its own, EPA comes almost entirely from what you eat or supplement. Your level is a direct readout of whether your intake is adequate.

What EPA Does in Your Body

EPA is a 20-carbon omega-3 fat that gets built into the outer membranes of cells throughout your body, including your blood vessel walls, immune cells, and brain cells. Once embedded in those membranes, it changes how cells behave in ways that matter for heart disease, inflammation, and mood.

When your body needs to mount or resolve an inflammatory response, it pulls fatty acids out of cell membranes and converts them into signaling molecules. If those membranes are rich in EPA, your cells produce a family of molecules called resolvins that actively shut down inflammation after it has done its job. They also produce less of the aggressive inflammatory signals that come from omega-6 fats like arachidonic acid.

EPA also improves how your blood vessels function by supporting nitric oxide production, the molecule that keeps arteries relaxed and open. It lowers triglycerides (the fat particles in your blood that carry energy from food), reduces the inflammatory content of arterial plaques, and helps your body clear cholesterol more efficiently through a process where HDL particles shuttle cholesterol back to the liver for disposal.

Heart Disease and Cardiovascular Events

The cardiovascular evidence for EPA is unusually strong for a nutrient biomarker. In the REDUCE-IT trial and other large studies of high-dose purified EPA, people with elevated triglycerides who were already taking statins saw about a 25% reduction in major cardiovascular events, including heart attacks, strokes, and cardiovascular death. The benefits tracked directly with how high their blood EPA levels climbed during treatment.

A meta-analysis pooling data from over 135,000 participants found that omega-3 supplementation reduced heart attacks, cardiovascular death, and the need for procedures to reopen blocked arteries. The reductions were consistently stronger in trials using EPA alone compared to those using EPA mixed with DHA (docosahexaenoic acid, the other major marine omega-3). This distinction matters if you are choosing a supplement.

What this means for you: if your EPA is low, you are carrying extra cardiovascular risk that does not show up on a standard lipid panel. This is true even if your LDL cholesterol is well controlled with a statin. The residual risk from low EPA appears to be independent of traditional risk factors.

Colorectal Cancer

A dose-response meta-analysis across 26 prospective studies found that each 1 percentage point increase in circulating EPA was associated with about a 14% lower risk of developing colorectal cancer. This association held after adjusting for standard risk factors and was based on over 14,000 participants with more than 3,400 cancer events. EPA is also being tested in a phase 3 trial for preventing colorectal cancer recurrence after liver surgery for metastases.

Depression and Brain Health

Two separate meta-analyses found that omega-3 supplements with EPA making up at least 60% of the total omega-3 content significantly improved depressive symptoms, while DHA-dominant formulations did not. The effective dose was around 1 gram per day. The International Society for Nutritional Psychiatry Research now recommends 1 to 2 grams of net EPA daily as part of depression treatment.

EPA also appears to support brain health through anti-inflammatory pathways, though most of the structural omega-3 in the brain is DHA. A 12-week randomized trial of 1.8 grams per day of EPA in people with episodic migraines reduced monthly migraine days, headache severity, disability, anxiety, and depression scores compared to placebo, with good tolerability.

Mortality

In a pooled analysis of 17 cohorts tracking over 42,000 people for a median of 16 years, those in the highest fifth of blood EPA had roughly 15% to 18% lower all-cause mortality and 13% to 21% lower cardiovascular mortality compared to the lowest fifth, after adjusting for conventional risk factors. In the Framingham Heart Study, the top fifth of red blood cell EPA+DHA had about 34% lower all-cause mortality and 39% fewer cardiovascular events compared to the bottom fifth over 7.3 years of follow-up.

One Wrinkle: EPA and DHA May Interact

An observation from multiple studies deserves attention. In a cohort of nearly 1,000 patients who had undergone heart catheterization, higher DHA appeared to blunt the cardiovascular protection from EPA. People with high EPA and a high EPA-to-DHA ratio had the best outcomes, while those with high DHA relative to EPA did not see the same benefit. A Chinese cohort of over 2,100 adults found that higher red blood cell EPA alone was actually associated with slightly higher risk of metabolic syndrome, but a higher DHA-to-EPA ratio was protective.

This does not mean EPA is harmful when DHA is present. It means the balance between these two fats may matter, and very high DHA without proportionally high EPA might dilute EPA's specific protective effects. For practical purposes, if you are supplementing for cardiovascular protection, an EPA-dominant formulation has the strongest evidence behind it.

Reference Ranges

EPA does not yet have universally standardized clinical cutpoints the way cholesterol or blood sugar do. Most of the clinical risk data uses the Omega-3 Index (EPA plus DHA combined, measured in red blood cells), with 8% or above considered optimal and 4% or below considered high risk. However, EPA-specific population data from large studies can help you orient around your result.

These values come from a US clinical laboratory database of over 1.1 million plasma samples and from the nationally representative NHANES survey of 2,261 adults. They are reported in different units depending on the study, so compare your result within the same lab and same units over time.

Your level will vary by age, sex, and geography. Women tend to run about 7% higher than men. Adults 65 and older have roughly 57% higher plasma EPA than adults under 30, largely reflecting diet differences. People in the US Northeast and West tend to have higher levels than those in the South and Midwest. Genetic variation in fat metabolism enzymes can also create large differences; a study of Mexican American adults found that certain gene variants drove EPA levels extremely low, which correlated with worse insulin resistance and triglycerides.

Tracking Your Trend

A single EPA reading is useful, but tracking over time is where this test becomes powerful. Because EPA reflects weeks of dietary intake, it responds meaningfully to changes in your fish consumption or supplementation, usually within 8 to 12 weeks. If you start taking an omega-3 supplement, retesting at 3 months tells you whether your chosen product, dose, and formulation are actually raising your level.

This matters because people absorb omega-3s differently. Genetic variation, the chemical form of your supplement (triglyceride forms raise levels more effectively than ethyl ester forms, gram for gram), your baseline level, and your background diet all influence how much your EPA moves. A study pooling data from 14 clinical trials found that the same dose of EPA+DHA raised the Omega-3 Index by about 1 full percentage point more when taken as triglycerides versus ethyl esters. You cannot know how you personally respond without measuring.

Get a baseline, retest in 3 months if you are making dietary changes or starting a supplement, and then recheck at least annually to confirm you are staying in range. If you are managing cardiovascular risk factors, twice-yearly testing is reasonable.

When Results Can Be Misleading

• A very recent fish meal (within 24 hours) can temporarily spike your plasma EPA without reflecting your usual status. For the most representative reading, maintain your normal diet but avoid an unusually large fish meal the day before your blood draw.
• The chemical form of your supplement affects how quickly and how much EPA appears in your blood. Triglyceride-based omega-3 supplements produce higher blood levels than ethyl ester forms at the same dose, so switching products can shift your number without changing your actual omega-3 status.
• Different labs measure EPA in different blood fractions (plasma, serum, red blood cells, whole blood) and report in different units. Results from one fraction cannot be directly compared to another. Always compare your results within the same lab and the same test method over time.
• Genetic variation in fatty acid metabolism enzymes can make two people with identical diets have very different EPA levels. If your level seems surprisingly low despite good fish intake or supplementation, genetic differences in how your body processes these fats may be the explanation.

What to Do with Your Result

If your EPA is in the lowest range for your lab, or if your Omega-3 Index (if available) is below 4%, that signals meaningful cardiovascular and inflammatory risk worth addressing. The next step is to assess your broader lipid picture with ApoB (apolipoprotein B, the best single measure of artery-clogging particles), triglycerides, and hs-CRP (high-sensitivity C-reactive protein, a marker of systemic inflammation). Together, these tell you whether low EPA is part of a larger pattern of residual cardiovascular risk.

If your EPA is adequate but your cardiovascular risk markers remain elevated, the issue is elsewhere. If your EPA is low and your triglycerides are high, that combination is exactly the profile where high-dose EPA intervention has shown the strongest benefit in clinical trials. If you are dealing with depression, a low EPA level alongside mood symptoms makes a strong case for an EPA-dominant omega-3 supplement as an adjunct to standard treatment.

For anyone with established heart disease, prior heart attack, or peripheral artery disease, EPA becomes especially relevant. In patients with peripheral artery disease affecting the leg arteries, those with plasma EPA below 57 µg/mL had about 2.7 times the risk of major adverse limb events and death compared to those above that threshold. Similarly, a low EPA-to-arachidonic acid ratio predicted worse outcomes after procedures to reopen blocked arteries. If you are in this population, knowing your EPA level helps you and your cardiologist or vascular specialist calibrate your omega-3 strategy.